Abstract
The role of postmastectomy radiation therapy (PMRT) for patients with T1–T2 tumors and 1–3 positive axillary lymph node (ALN) metastases of breast cancer is an issue of ongoing debate. The uncertainty and controversy concerning PMRT for this group of patients is mainly due to the discrepancy in the conflicting benefits of locoregional control reported in different trials and in adjuvant systemic treatment eras (1-4).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
